{
    "nctId": "NCT00622466",
    "briefTitle": "Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Time to Tumor Progression",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nInclusion criteria:\n\n* Histologically\\* confirmed breast cancer\n\n  * Stage IV (metastatic) disease\n\n    * Radiographic evidence of metastases NOTE: \\*Histological confirmation of the actual metastasis is not required.\n* Measurable disease by RECIST criteria defined as \u2265 1 unidimensionally measurable lesion \u2265 20 mm by conventional techniques (i.e., physical examination, CT scan, MRI, or x-ray) or \u2265 10 mm by spiral CT scan\n\n  * No prior radiotherapy unless growth has been documented following radiotherapy\n* Primary tumor or metastatic tumor HER2-negative, defined as the following:\n\n  * Immunohistochemistry of 0 or 1+ OR the equivalent, if an automated quantitative assay is used\n  * HER2 fluorescent in situ hybridization (FISH) assay negative as defined by a HER2:chromosome 17 centromeric probe ratio \\< 1.8 (or \\< 2.2 if immunohistochemistry is less than 3+ or equivalent) OR equivalent values for negative FISH assays that do not normalize to chromosome 17\n* Hormone-receptor positive (estrogen receptor-\\[ER\\] or progesterone receptor \\[PgR\\]-positive) disease or hormone receptor-negative (ER- or PgR-negative) disease\n* Tumor block from initial breast cancer primary or a biopsy of a metastatic site must be available for correlative studies\n* Brain metastases allowed provided the patient is stable after completion of treatment (i.e., surgery and/or radiotherapy), asymptomatic, and off steroids with 2 consecutive stable brain scans at least 4 weeks after radiotherapy\n\nExclusion criteria:\n\n* Bone-only or other nonmeasurable-only disease\n* Newly diagnosed brain metastases\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* ECOG performance status 0-1\n* Life expectancy \\> 6 months\n* Menopausal status not specified\n* WBC \u2265 3,000/mcL\n* Absolute neutrophil count \u2265 1,500/mcL\n* Platelets \u2265 100,000/mcL\n* Total bilirubin \\< 1.5 times upper limit of normal (ULN)\n* AST and ALT transaminases \u2264 2.5 times ULN (\\< 5 times ULN if liver involvement)\n* Creatinine \\< 1.5 times ULN OR creatinine clearance \\> 60 mL/min\n* INR \\< 1.5 OR PT/PTT normal\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception prior to and during (women and men) and for at least 3 months after (men) study therapy\n* Able to swallow and absorb oral medications\n\nExclusion criteria:\n\n* Active or uncontrolled medical illness (e.g., active infection \\> CTCAE grade 2), including any of the following:\n\n  * HIV or chronic hepatitis B or C\n  * Uncontrolled diabetes\n  * NYHA class II-IV uncompensated congestive heart failure\n  * Unstable angina (anginal symptoms at rest)\n  * New onset angina (i.e., began within the past 3 months)\n  * Coronary artery disease\n* Myocardial infarction within the past 6 months\n* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\n* Evidence of bleeding diathesis or coagulopathy\n* Pulmonary hemorrhage/bleeding event \\> CTCAE grade 2 within 4 weeks of first dose of study drug\n* Any other hemorrhage/bleeding event \\> CTCAE grade 3 within 4 weeks of first study drug\n* Thrombotic or embolic events (i.e., cerebrovascular accident), including transient ischemic attacks within the past 6 months\n* Hypertension that cannot be controlled with medication to \u2264 150/90 mm Hg\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib tosylate\n* Prior invasive cancer other than breast cancer except nonmelanoma skin cancer\n* Chronic nonhealing wound or ulcer\n\nPRIOR CONCURRENT THERAPY:\n\n* No more than 1 prior chemotherapy regimen for metastatic breast cancer (MBC)\n* At least 3 weeks since prior hormonal therapy for MBC or adjuvant or neoadjuvant chemotherapy\n\n  * More than 1 year since adjuvant paclitaxel\n* At least 4 weeks since major thoracic, abdominal, or pelvic surgery and recovered\n* At least 3 weeks since prior and no concurrent investigational drugs\n* Concurrent bisphosphonates allowed\n* Concurrent anticoagulation agents (i.e., warfarin or heparin) allowed\n* No anticipated need for or concurrent radiotherapy\n* No concurrent Hypericum perforatum (St. John wort) or rifampin (rifampicin)\n* No other concurrent anti-neoplastic drugs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}